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High-field MR-linaca b s t r a c t
Introduction: MR-guided adapted radiotherapy (MRgART) using a high field MR-linac has recently
become available. We report the estimated delivered fractional dose of the first five prostate cancer
patients treated at our centre using MRgART and compare this to C-Arm linac daily Image Guided
Radiotherapy (IGRT).
Methods: Patients were treated using adapted treatment plans shaped to their daily anatomy. The treat-
ments were recalculated on an MR image acquired immediately prior to treatment delivery in order to
estimate the delivered fractional dose. C-arm linac non-adapted VMAT treatment plans were recalculated
on the same MR images to estimate the fractional dose that would have been delivered using conven-
tional radiotherapy techniques using a daily IGRT protocol.
Results: 95% and 93% of mandatory target coverage objectives and organ at risk dose constraints were
achieved by MRgART and C-arm linac delivered dose estimates, respectively. Both delivery techniques
were estimated to have achieved 98% of mandatory Organ At Risk (OAR) dose constraints whereas for
the target clinical goals, 86% and 80% were achieved by MRgART and C-arm linac delivered dose esti-
mates.
Conclusions: Prostate MRgART can be delivered using the a high field MR-linac. Radiotherapy performed
on a C-arm linac offers a good solution for prostate cancer patients who present with favourable anatomy
at the time of reference imaging and demonstrate stable anatomy throughout the course of their treat-
ment. For patients with critical OARs abutting target volumes on their reference image we have demon-
strated the potential for a target dose coverage improvement for MRgART compared to C-arm linac
treatment.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).1. Introduction
The Elekta Unity MR-linac (MRL) (Elekta AB, Stockhom, Swe-
den) combines a high field 1.5 T Philips Magnetic Resonance
(MR) scanner (Philips Medical Systems, Best, The Netherlands)
and a 7MV FFF Elekta linear accelerator [1–3]. The superior soft-tissue contrast [4,5], when compared to Computed Tomography
(CT) and Cone Beam CT (CBCT), available with the MRL should
enable improved pre-treatment image verification whilst the unit
also facilitates MR-guided adaptive radiotherapy (MRgART) by
allowing treatment plans to be designed on the MR image acquired
prior to treatment accounting for the current anatomy.
The MRL potentially offers advantages for prostate cancer radio-
therapy compared to C-arm linac treatments. The improved visual-
isation of the patient’s anatomy on MR [4,5], compared to CT,
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observer variation of target volume delineation [7]. Substantial
interfraction anatomical variation is observed for a subset of pros-
tate cancer patients [7]. The ability to generate MRgART treatment
plans on the MRL means the treatment can be shaped to the anat-
omy of the patient in their treatment position directly prior to
treatment [8,9] as opposed to the anatomical snapshot acquired
during simulation imaging in the conventional radiotherapy work-
flow which could up to two weeks before treatment. Improved tar-
get visibility along with the ability to adapt to the daily anatomy
may in turn lead to reduced clinical target volume (CTV) to plan-
ning target volume (PTV) margins [6] and potentially enable the
implementation of more profound hypofractionation for prostate
cancer [6], such as five, three, two, or even single fraction regimes,
where accurate delivery and dose constraint compliance of every
fraction will be essential. The MRL is also able to acquire real-
time MR images as the treatment beam is being delivered meaning
intrafraction organ motion can be observed and, in the future, be
accounted for via gating or tracking techniques [10–14].
Low field (0.35T) MRgART has been available since 2014 using
the MRIdian treatment unit (ViewRay, Inc., CA, US) [15–17]. Recent
studies have shown that 0.35T-based MRgART for prostate cancer
resulted in a low incidence of toxicity for stereotactic body radia-
tion therapy (SBRT) [15] and that adaptive planning can be benefi-
cial when considerable interfraction organ motion is observed [16].
MRgART, with diagnostic-quality high field MR images, using the
MRL has been in clinical use globally since 2017 [3] and 2018 at
our centre. Feasibility of MRgART using the MRL has recently been
reported [18] but, to our knowledge, no study has reported a dosi-
metric comparison between this and standard C-arm linac delivery
for prostate cancer.
The PRISM (Prostate Radiotherapy Integrated with Simultane-
ous MRI; NCT 03658525) trial aims to assess the feasibility, safety,
and tolerability of MRL-guided prostate radiotherapy [6]. In this
paper we describe the clinical implementation of high-field MR-
guided adaptive radiotherapy (MRgART) for patients having MRL
prostate radiotherapy within the PRISM trial and evaluate esti-
mates of delivered dose for the first five prostate cancer patients
reported to have received daily MRgART using the MRL. We com-
pare these results with estimates of delivered doses with treat-
ment using daily IGRT on a C-arm linac and to our knowledge
this represents the first reported dosimetric comparison between
MRgART using the MRL and C-arm-based IGRT delivery2. Methods
The first five patients recruited to PRISM were included in this
study. The primary ‘prostate CTV’ is defined as the prostate and
proximal 1 cm of seminal vesicles with a secondary CTV (‘SV
CTV’) consisting of the proximal 2 cm of seminal vesicles exterior
to the prostate CTV. The CTV to PTV margins, target coverage
requirements, and Organ at Risk (OAR) constraints (Table S1) are
the same as for conventional daily-online IGRT on a C-arm linac
at our centre (Table S1).2.1. Treatment planning
The MRL has two modes of operation: Adapt-To-Position (ATP)
and Adapt-To-Shape (ATS), with both online planning methods
requiring an initial reference treatment plan to be generated on
a reference image (CT or MR) [9,19]. Bladder and rectal prepara-
tion was followed to ensure patients were treated with a comfort-
ably full bladder throughout treatment and scanned without a
distended rectum Reference Planning CT scans were acquired
with 1.5 mm slice thickness with patients immobilized usingthe Combi Fix system (Oncology Systems Ltd, UK). Bladder and
rectal preparation was followed to ensure patients were treated
with a comfortably full bladder throughout treatment and
scanned without a distended rectum. MRL reference plans gener-
ated on the reference CT image used a 7-field IMRT simultaneous
integrated boost technique to deliver 60 Gy and 48.6 Gy in 20
fractions to the primary (PTV_6000) and elective PTVs
(PTV_4860), respectively (see Table S1). Dose was calculated to
medium using a 0.3 cm isotropic dose grid and 2% statistical
uncertainty per plan. Ten segment shape optimisation (SSO) loops
were used to generate the reference plans with a maximum of 60
segments, minimum segment area of 4 cm2, and minimum of 3
monitor units per segment allowed. After optimisation, the mon-
itor units were re-scaled so that the primary PTV D50% was
60.0 Gy. VMAT Backup treatment plans for a C-arm Elekta Agility
linac were generated in the event the MR-linac was not available
for treatment and were of the same quality as our standard non-
trial prostate plans. Treatment plans for the MRL (both reference
and online) were generated using the Monaco (Elekta AB, Stock-
holm, Sweden, V5.40.00) treatment planning system (TPS) using
the GPUMCD [20,21] dose calculation algorithm and backup plans
were generated using the RayStation TPS (Raysearch Laboratories,
Stockholm, Sweden, V8.0.0.61) with a collapsed cone dose calcu-
lation algorithm.
ATP treatment consists of acquiring a daily MR image, register-
ing this with the reference image, and then adapting the Multi Leaf
Collimator (MLC) leaves according to the translations-only rigid
registration. The adapted plan is recalculated on the reference
image and therefore does not account for inter-fraction anatomical
changes. This methodology is akin to daily IGRT-based corrected
treatment on a C-arm linac but with MLC leaf adaption to avoid
moving the couch in the confined bore of the MRL. In ATS a
deformable image registration is performed between the reference
and daily images and contours are propagated to the daily image
according to this registration. The propagated contours are edited
if necessary according to the daily anatomy and a treatment plan
is optimised and calculated on the daily image.2.2. Online plan adaption strategy
Fig. 1 illustrates the online MRgART ATS-based workflow imple-
mented to treat PRISM patients at our centre. After a daily ‘online’
plan was generated, checks were carried out to ensure plan param-
eters were as expected whilst the clinician approved the dose dis-
tribution. A secondary dose calculation was then performed using
the RayStation TPS and a second MR image was acquired (MR ver-
ification image). For online plans, the only modification from the
reference plan technique was to perform 5 SSO loops to maintain
acceptable online planning times. Dose calculation for the MRgART
daily treatment plans was facilitated using a bulk density override
method whereby patient-specific overrides were applied to the
combined CTVs, bones, and the patient external contour.
If anatomical motion was observed between the time of initial
daily MR acquisition and treatment delivery such that the prostate
CTV was not completely within the corresponding PTV on the ver-
ification image, an ATP of the ATS plan was performed This work-
flow was implemented from the second patient onwards, for the
first case ATS-only plans were generated and delivered.2.3. Delivered fractional dose estimation
In order to estimate the fractional delivered dose, the clinically
delivered MRL plans were recalculated on the verification MR
image using the same bulk-density override strategy as for the
daily image. The verification image and corresponding dose cube
Fig. 1. Online MRgART strategy for PRISM patients investigated in this study. Actions in black, green, and blue were performed by radiographers, clinicians, and physicists,
respectively. The Motion Monitoring cine MR is acquired throughout entire treatment delivery. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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toured target structures (prostate and SV CTVs) and OARs (in order
to estimate the delivered fractional dose.
The RayStation TPS-generated VMAT backup plans were used to
estimate the fractional dose that would have been delivered on a C-
arm linac using a daily online correction IGRT protocol. A soft
tissue-based rigid registration was performed by therapeutic
radiographers between the reference and daily verification images
with the reference image prostate CTV visible thereby mimicking
daily online CBCT to CT image matching. The backup plans were
then recalculated on each daily verification MR image using the
same bulk-density assignment as for the MRL plan calculations.
In order to remove systematic differences resulting from the
backup and MRL plans being generated in different TPSs with dif-
ferent dose calculation strategies (backup plan generated on the
reference CT using a HU-to-density look-up-table and the MRL
plans generated using bulk-density assignment), the monitor units
of the backup plans were adjusted (average adjustment was 1.5%
with standard deviation of 0.2%) so that the primary PTV D50% was
60.0 Gy when the plan was calculated on the reference CT with
bulk-density assignments applied as per MRL treatment. Target
and OAR dose were then assessed using the clinician-defined ver-
ification image ROIs.2.4. Data analysis
Each estimate of fractional dose was scaled to 20 fractions to
assess mandatory and optimal clinical goal compliance
(Table S1). For the delivered fractional dose estimates the PTV clin-
ical goals were applied to the corresponding CTVs. The dose cubes
from the Monaco-generated plans were imported into the RaySta-
tion TPS and all dose-volume data were extracted from the RaySta-
tion TPS for analysis. All statistical analysis was performed using
Python (v2.7.6).3. Results
The MRgART online workflow took 45 min on average. Two
fractions were excluded from the analysis due to amended treat-
ment workflows (resulting from hardware and software errors)
thus a total of 98 fractions were analysed in this study. Of the 98
analysed fractions, 18 ATP of ATS plans were performed with the
remaining 80 fractions being ATS-only workflows.
Table 1 details the results for the mandatory clinical goal dose
metrics for the clinical MRL and C-arm linac fractional delivered
dose estimates. Of all the assessed mandatory clinical goals, 95%
Table 1
Mandatory clinical goal compliance for estimates of delivered fractional dose for five patients treated on the MRL along with corresponding C-arm linac estimates. SD (standard
deviation).
MRL delivered dose Simulated C-arm linac delivered dose
ROI metric mandatory clinical goal Mean SD % meeting goal Mean SD % meeting goal
Prostate CTV D99% n/a 56.2 Gy 2.6 Gy n/a 55.7 Gy 4.9 Gy n/a
D98% > 55.8 Gy 56.9 Gy 2.2 Gy 83.7 56.8 Gy 3.5 Gy 77.6
D95% > 57.0 Gy 57.9 Gy 1.4 Gy 83.7 57.9 Gy 2.5 Gy 81.6
SV CTV D99% n/a 49.8 Gy 5.6 Gy n/a 48.2 Gy 7.5 Gy n/a
D98% > 45.2 Gy 50.6 Gy 5.1 Gy 86.7 48.9 Gy 7.1 Gy 80.6
D95% > 46.2 Gy 51.8 Gy 4.6 Gy 88.8 50.2 Gy 6.5 Gy 80.6
Rectum V60.8 Gy < 5% 0.6% 1.0% 99.0 0.0% 0.1% 100.0
V56.8 Gy < 15% 6.0% 4.5% 95.9 6.5% 3.3% 100.0
V52.7 Gy < 30% 12.5% 6.7% 100.0 11.8% 4.8% 100.0
V48.6 Gy < 50% 18.7% 8.4% 100.0 16.5% 5.6% 100.0
V40.5 Gy < 60% 32.4% 11.3% 100.0 26.5% 7.0% 100.0
Bladder V60.8 Gy < 25% 1.2% 1.0% 100.0 0.1% 0.2% 100.0
V56.8 Gy < 35% 6.5% 2.8% 100.0 3.0% 1.9% 100.0
V52.7 Gy < 50% 10.1% 4.4% 100.0 5.0% 2.9% 100.0
Bowel V52.7 Gy < 0.01 cc 0.0 cc 0.2 cc 87.8 0.0 cc 0.2 cc 86.7
V48.7 Gy < 6 cc 0.1 cc 0.4 cc 100.0 0.2 cc 0.8 cc 98.9
D0.01 cc < 52.7 Gy 36.3 Gy 17.5 Gy 88.8 35.5 Gy 18.4 Gy 86.7
Penile Bulb V40.5 Gy < 50% 7.0% 8.7% 100.0 5.3% 7.0% 100.0
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ered dose estimates, respectively. Both delivery techniques were
estimated to have achieved 98% of mandatory OAR clinical goals
whereas for the target clinical goals, 86% and 80% were achieved
by the clinical MRL and C-arm linac delivered dose estimates,
respectively.
Fig. 2 displays clinical MRL and C-arm linac fractional dose esti-
mates for a patient (case 3) who presented with unfavourable
anatomy at their reference scan (bowel loop adjacent to the CTV)
and exhibited highly variable inter-fraction anatomical motion.Fig. 2. Estimates of delivered dose from case 3. Main figure: boxplots comparing the t
constraint for the estimates of the clinical MRL and C-arm linac fractional delivered dose e
respectively. Inset: an example fractional delivered dose DVH estimate with prostate CT
and C-arm linac estimates are shown as solid and dashed lines. For both the boxplots an
interpretation of the references to colour in this figure legend, the reader is referred toFig. 3 displays the corresponding results for a patient (case 4) with
favourable and stable anatomy. For this patient the C-arm linac
backup plan and MRL reference plan compromised target coverage
to ensure the bowel 52.7 Gy maximum dose constraint was
achieved. However, this patient exhibited significant inter-
fraction anatomical motion of both the target structures and OARs
(Fig. 4). For a proportion of fractions the bowel had moved away
from the target volumes meaning the clinically-delivered MRgART
plan was able to achieve target coverage requirements (Table S1)
on these days. The non-adaptive C-arm linac plans could notarget coverage dose-volume metrics and critical bowel mandatory maximum dose
stimates. Mandatory and optimal clinical goal levels are shown as red and gold lines,
V, SV CTV, and bowel shown as purple, cyan, and yellow, respectively. Clinical MRL
d DVHs, all estimates of fractional delivered dose were scaled to 20 fractions. (For
the web version of this article.)
Fig. 3. Estimates of delivered dose from case 4. Main figure: boxplots comparing the target coverage dose-volume metrics and critical bowel mandatory maximum dose
constraint for the estimates of the clinical MRL and C-arm linac fractional delivered dose estimates. Mandatory and optimal clinical goal levels are shown as red and gold lines,
respectively. Inset: an example fractional delivered dose DVH estimate with prostate CTV, SV CTV, and bowel shown as purple, cyan, and yellow, respectively. Clinical MRL
and C-arm linac estimates are shown as solid and dashed lines. For both the boxplots and DVHs, all estimates of fractional delivered dose were scaled to 20 fractions. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Axial (top row) and sagittal (bottom row) images of case 3 from the planning CT (left column), #5 verification MR acquisition (centre column), and #6 verification MR
acquisition (right column). In all images, the prostate CTV (including proximal 1 cm seminal vesicles), SV CTV, and bowel are shown as red, cyan, and yellow contours,
respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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coverage was compromised for all fractions. For the mandatory tar-
get coverage clinical goals for case 3, we estimate that with
MRgART the prostate CTV D98%, prostate CTV D95%, SV CTV
D98%, and SV CTV D95% received on average 54.5 Gy, 57.4 Gy,
45.2 Gy, and 46.5 Gy, respectively with all average results apart
from the prostate CTV D98% meeting the mandatory clinical goal.
The corresponding estimates for the C-arm linac were 49.9 Gy,53.9 Gy, 37.0 Gy, and 40.5 Gy, with all averages failing to meet
the mandatory clinical goal and representing a range of decreases
of 4.6–8.2 Gy compared to the MRgART estimates, equivalent to
approximately two additional fractions on the MRL compared to
a C-arm linac whilst achieving the same mandatory OAR clinical
goal compliance (98% mandatory OAR clinical goal compliance
for both MRL and C-arm linac fractional dose estimates). For case
3, 40% of MRL fractional dose estimates achieved the optimal SV
40 A. Dunlop et al. / Clinical and Translational Radiation Oncology 23 (2020) 35–42CTV clinical goal whereas none of the C-arm linac plans achieved
this.
For case 4 (Fig. 3) the patient had bowel far away from target
volumes at the time of reference scanning and for every fraction
meaning no target compromise was necessary during backup and
reference planning. Case 4 was representative of all cases in this
study apart from case 3. No significant inter-fraction motion was
observed meaning the C-arm linac plan was able to achieve compa-
rable target coverage to the MRgART delivered dose estimates with
both techniques estimated to achieve 96% of mandatory target
clinical goals.
Out of the 98 comparisons of the prostate CTV D95% metric, the
C-arm linac plan achieved a higher CTV D95% compared to the clin-
ical MRgART plan on 71 occasions. The mean CTV prostate D95%
out of these 71 cases was 58.8 Gy and 58.0 Gy for the C-arm linac
and MRgART estimates, respectively, with both being above the
mandatory clinical goal. However, for the remaining 27 cases the
mean CTV prostate D95% was 55.2 Gy (<57.0 Gy) and 57.5 Gy for
the C-arm linac and MRgART estimates. This indicates that when
the C-arm linac plan achieves a higher CTV prostate D95% it is
not clinically relevant, whereas for fractions in which the opposite
is true the possibility of a clinical impact remains. A corresponding
analysis shows similar results for the CTV prostate D98%. Similar to
the prostate CTV, for the SV CTV the MRgART achieved the manda-
tory target coverage clinical goals more often than the C-arm linac
plan (Table 1).
Almost all mandatory OAR clinical goals were achieved for each
fractional delivered dose estimate for both the MRgART and C-arm
linac plan, however, differences were observed for the rectum
V60.8 Gy, low dose rectum, and bladder comparisons and these dif-
ferences are displayed graphically for all rectum clinical goals in
Fig. 5. 79% and 86% of optimal bladder dose constraints were
achieved by the clinical MRgART and C-arm linac delivered doseFig. 5. Estimates of delivered rectum dose for all five cases investigated in this study. B
clinical MRL and C-arm linac fractional delivered dose estimates. Mandatory and optim
fractional delivered dose were scaled to 20 fractions. (For interpretation of the referenc
article.)estimates, respectively. The corresponding results for the optimal
rectum clinical goals were 91% and 100%. The results for other
OARs listed in Table S1 were similar for both delivery techniques.4. Discussion
By estimating delivered fractional doses of MRgART plans we
have demonstrated feasibility of prostate treatment on the MRL
and, similar to results presented for low-field MRgART [16], the
high-field MR guided adapted technique offers a target coverage
advantage over a C-arm linac for patients who present with unfa-
vourable anatomy at the time of reference imaging and/or demon-
strate significant inter-fraction anatomical variation. We have
demonstrated that for patients with unfavourable anatomy, who
exhibit an OAR adjacent to the target resulting in target compro-
mise, at the time of reference imaging, MRgART can deliver full tar-
get dose for those days when the anatomy is more favourable with
critical OARs away from the target volume. Conversely, for patients
who present for a fraction with unfavourable anatomy, we have
the opportunity to maintain OAR constraint compliance by com-
promising the target on that day. Such an approach should be
undertaken with caution given that C-arm linac radiotherapy, from
which OAR clinical goals are based, does not adapt dose distribu-
tions and limit target dose in this way and toxicity outcomes are
considered acceptable [22]. However, with the MRL we now have
the opportunity to visualise targets and OARs during treatment
delivery which will enable the chance to explore new compromises
between tumour control and toxicity in the future.
For the 28% of fractions where the CTV prostate D95% was esti-
mated to be higher for the MRgART compared to C-arm linac treat-
ment, the magnitude of detriment (55.2 Gy vs 57.5 Gy) was likely
to have clinical implications. The CHHiP trial demonstrated thatoxplots compare rectum dose-volume clinical goal metrics for the estimates of the
al clinical goal levels are shown as red and gold lines, respectively. All estimates of
es to colour in this figure legend, the reader is referred to the web version of this
A. Dunlop et al. / Clinical and Translational Radiation Oncology 23 (2020) 35–42 4157 Gy in 19 fractions could not be considered non-inferior to 74 Gy
in 37 fractions (itself non-inferior to 60 Gy in 20 fractions) so a
detriment of 2.3 Gy in 20 fractions may be enough to compromise
biochemical control [22].
For one fraction the clinical MRgART failed to meet the manda-
tory rectum V60.8 Gy clinical goal. Retrospective analysis of this
fraction showed that this clinical goal would have been achieved
had an ATP been performed based on the verification image regis-
tration (right branch of Fig. 1), highlighting the need to perform the
ATP when appropriate. This analysis also demonstrates that radio-
therapy performed on a C-arm linac offers a good solution for
patients who present with favourable anatomy at the time of ref-
erence imaging and demonstrate stable anatomy throughout the
course of their treatment. Indeed, if case 3 is excluded from the
analysis 98% of mandatory clinical goals were achieved by the
MRgART and C-arm linac delivered dose estimates. However, we
cannot currently predict which patients may benefit from MRgART
based on the reference image, meaning that if more profound
hypofractionation for prostate radiotherapy is to be realised,
MRgART using the MRL may be the most appropriate treatment
technique.
We have observed proportions of the rectum and bladder
receiving low doses for MRgART compared to C-arm linac frac-
tional dose estimates. This is due to two main reasons. Firstly,
the MRL is only currently able to deliver fixed-field IMRT treat-
ments, compared to the VMAT technique used for the backup
plans. Secondly, as part of the decision to implement an MRgART
workflow using ATS, we did not attempt to achieve the lowest pos-
sible OAR dose in our reference plans as when this plan is propa-
gated to the daily image for adaptive re-planning excessive OAR
sparing on the daily geometry can result in unnecessary target
compromise. This can be because either the daily anatomy is less
favourable than on the reference image or, given that online plan-
ning has to occur in a timely fashion, the online optimisation does
not have enough time to achieve full target coverage at the lowest
achievable OAR dose. Therefore, this study compares the estimates
of the MRL and daily IGRT C-arm treatment planning strategies
that have been implemented in our department and does not rep-
resent the best dose distributions that can be achieved. This study
describes our first implementation of MRgART using an MRL and as
more patients are treated we aim to refine and improve on the
planning strategy. It is hoped that with enhanced delivery capabil-
ities on the MRL (such as VMAT delivery), faster online optimisa-
tion allowing OARs to be optimised to a lower dose without
compromising targets, and with the opportunity to reduce CTV to
PTV margins with MRgART, we should be able to achieve lower
OAR dose using the MRL, when compared to a C-arm linac.
Alongside affording CTV to PTV margin reduction due to
improved target visualisation and image registration (which
would, given the currently-implemented workflow, necessitate
more ATP of ATS plans) and the opportunity to deliver more pro-
found hypofractionated treatment regimes, MRgART allows the
possibility in the future to deliver a boost dose to the daily position
of the dominant lesion visible on MR as well as enabling real-time
soft-tissue tracking to account for intra-fraction motion, making
MRgART using the MRL an attractive option for prostate cancer
treatment going forwards.5. Conclusions
Prostate MRgART is feasible to deliver using a high field MR-
linac with the full daily adaptive re-planning workflow. When
using standard CTV to PTV margins, radiotherapy performed on a
C-arm linac offers a good solution for prostate cancer patients
who present with favourable anatomy at the time of referenceimaging and demonstrate stable anatomy throughout the course
of their treatment. For patients with organs at risk abutting target
volumes on their reference image which would necessitate target
coverage compromise using a conventional non-adaptive radio-
therapy technique, we have demonstrated the potential for target
dose coverage improvement for MRgART on an MRL compared to
C-arm linac daily IGRT treatment. The ability to adapt treatments
to patient anatomy immediately prior to treatment delivery makes
MRgART an attractive modality in the future for more profound
hypofractionation treatment for prostate cancer.
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